CervoMed posts 2023 net loss of $2.2M; secures $50M private placement; Phase 2b DLB trial on track

CervoMed Inc.

Net loss $2.2M for 2023; cash $7.8M as of Dec 31, 2023; R&D spending increased to $8.4M.
Private placement of $50M upfront (up to $149.4M with warrants) led by RA Capital; expected to fund through end of 2025.
RewinD-LB Phase 2b enrollment on track to complete Q2 2024; topline data expected Q4 2024.
Appointed Joshua Boger, founder of Vertex Pharmaceuticals, as non-executive Chair of the Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CervoMed Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2023. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-011212

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.